Dr Stephen Man

2021

• Rastogi, N.et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193(1), pp. 155-159. (10.1111/bjh.17125)

2020

• Elston, L.et al. 2020. Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL. British Journal of Haematology 188(6), pp. 872-880. (10.1111/bjh.16260)

2019

• Man, S. and Henley, P. 2019. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British Journal of Haematology 186(2), pp. 220-233. (10.1111/bjh.15918)

2018

• Pirotte, E. F.et al. 2018. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. PLoS ONE 13(12), pp. -., article number: e0207934. (10.1371/journal.pone.0207934)

2017

• Dockree, T.et al. 2017. CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold. Immunology and Cell Biology 95(1), pp. 68-76. (10.1038/icb.2016.85)

2016

• Parry, H. . M.et al. 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91(8), pp. 776-781. (10.1002/ajh.24403)
• Sacco, J. J.et al. 2016. Systemic listeriosis following vaccination with the attenuatedListeria monocytogenestherapeutic vaccine, ADXS11-001. Human Vaccines & Immunotherapeutics 12(4), pp. 1085-1086. (10.1080/21645515.2015.1121338)

2015

• Coles, S. J.et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29, pp. 1952-1954. (10.1038/leu.2015.62)
• Reid, R.et al. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144(3), pp. 495-505. (10.1111/imm.12398)

2014

• Tristram, A.et al. 2014. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology 15(12), pp. 1361-1368. (10.1016/S1470-2045(14)70456-5)
• Stanton, R. J.et al. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host and Microbe 16(2), pp. 201-214. (10.1016/j.chom.2014.07.005)

2013

• Wong, R. F.et al. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98(12), pp. 1930-1938. (10.3324/haematol.2012.082248)
• Al-Taei, S.et al. 2013. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunology, Immunotherapy 62(12), pp. 1821-1830. (10.1007/s00262-013-1488-5)
• Man, S. 2013. Back to the future: learning from cancer vaccine trials in Cardiff. Applied Immunohistochemistry and Molecular Morphology 21(2), pp. 110-115. (10.1097/PAI.0b013e3182811612)

2012

• Coles, S.et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26(9), pp. 2148-2151. (10.1038/leu.2012.77)
• Coles, S.et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26(9), pp. 2146-2148. (10.1038/leu.2012.75)
• Nunes, C. T.et al. 2012. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 18(3), pp. 678-687. (10.1158/1078-0432.CCR-11-2630)

2011

• Coles, S.et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135(S1), pp. 178. (10.1111/j.1365-2567.2011.03534.x)
• Nunes, C. T.et al. 2011. A novel tumor antigen derived from enhanced degradation of Bax protein in human cancers. Cancer Research 71(16), pp. 5435-5444. (10.1158/0008-5472.CAN-11-0393)
• Chan, P. K. S.et al. 2011. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. Journal of Medical Virology 83(6), pp. 1023-1030. (10.1002/jmv.21889)
• Coles, S.et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25(5), pp. 792-799. (10.1038/leu.2011.1)

2010

• Campo, M. S.et al. 2010. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407(1), pp. 137-142. (10.1016/j.virol.2010.07.044)
• Coles, S.et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116(21), pp. 218-218.
• Chan, P. K. S.et al. 2010. T-Cell response to human papillomavirus type 58 L1, E6, and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clinical and Vaccine Immunology 17(9), pp. 1315-1321. (10.1128/CVI.00105-10)

2008

• Thomas, K. J.et al. 2008. HPV16 E629-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. International Journal of Cancer 122(12), pp. 2791-2799. (10.1002/ijc.23475)
• Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2. Springer, pp. 129-160., (10.1007/978-1-4020-8442-3)

2007

• Capper, R.et al. 2007. The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes and Development 21(19), pp. 2495-2508. (10.1101/gad.439107)

2006

• McCarthy, C., Youde, S. J. and Man, S. T. 2006. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. International Journal of Cancer 118(10), pp. 2514-21. (10.1002/ijc.21643)
• Fiander, A. N.et al. 2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. International Journal of Gynecological Cancer 16(3), pp. 1075-1081. (10.1111/j.1525-1438.2006.00598.x)

2005

• Youde, S. J.et al. 2005. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. International Journal of Cancer 114(4), pp. 606-12. (10.1002/ijc.20779)
• Smith, K. L.et al. 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. International Immunology 17(2), pp. 167-176. (10.1093/intimm/dxh197)
• Hill, S. C.et al. 2005. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Journal of Immunology 174(1), pp. 41-50.
• Wall, S. R.et al. 2005. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. British Journal of Cancer 93(9), pp. 1068-1076. (10.1038/sj.bjc.6602736)
• Lyons, G. E.et al. 2005. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunology, Immunotherapy 55(9), pp. 1142-1150. (10.1007/s00262-005-0103-9)

2004

• Man, S. T.et al. 2004. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103(12), pp. 4613-4615. (10.1182/blood-2003-11-3903)
• Smyth, L. J. C.et al. 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clinical Cancer Research 10(9), pp. 2954-2961. (10.1158/1078-0432.CCR-03-0703)

2003

• Adams, M.et al. 2003. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21(7-8), pp. 787-90. (10.1016/S0264-410X(02)00599-6)
• Fiander, A. N. and Man, S. T. 2003. Antiviral vaccination for treating intraepithelial neoplasia. In: Maclean, A. B., Singer, A. and Critchley, H. eds. Lower Genital Tract Neoplasia. London: RCOG Press, pp. 192-209.

2002

• Savage, P.et al. 2002. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. British Journal of Cancer 86(8), pp. 1336-1342. (10.1038/sj.bjc.6600223)
• Savage, P.et al. 2002. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer 98(4), pp. 561-566. (10.1002/ijc.10219)

2001

• Evans, M.et al. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. The Journal of Immunology 167(9), pp. 5420-5428.
• Man, S. T. and Fiander, A. N. 2001. Immunology of human papillomavirus infection in lower genital tract neoplasia [review]. Best Practice & Research Clinical Obstetrics & Gynaecology 15(5), pp. 701-714. (10.1053/beog.2001.0215)
• Adams, M.et al. 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19(17-19), pp. 2549-2556. (10.1016/S0264-410X(00)00488-6)
• Adams, M.et al. 2001. Clinical studies of human papilloma vaccines in cervical cancer. In: Mackiewicz, A., Kurpisz, M. and Zeromski, J. eds. Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology Vol. 442. New York: Kluwer Academic/Plenum Publishers, pp. 419-427., (10.1007/978-1-4615-0685-0_61)
• Man, S. T. 2001. Recognition of human tumours: viral antigens as immunological targets for cytotoxic T cells. In: Robbins, R. A. and Rees, R. eds. Cancer Immunology. Immunology and Medicine Vol. 30. Springer, pp. 123-145.
• Lawson, T.et al. 2001. Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. International Immunology 13(11), pp. 1373-1381. (10.1093/intimm/13.11.1373)
• Lawson, T.et al. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. International Immunology 13(11), pp. 1383-1390. (10.1093/intimm/13.11.1383)

2000

• Youde, S. J.et al. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Research 60(2), pp. 365-371.
• Evans, M., Man, S. T. and Borysiewicz, L. K. 2000. Vaccine strategies for cancer. In: Weissberg, P. ed. Horizons in Medicine., Vol. 12. London: Royal College of Physicians, pp. 289-300.
• Borysiewicz., L. K. and Man, S. T. 2000. Vaccinia-based human papillomavirus vaccines in cervical cancer. In: Stern, P. L., Beverley, P. C. L. and Carroll, M. W. eds. Cancer vaccines and immunotherapy. Cambridge, UK: Cambridge University Press, pp. 62-81.

1999

• Man, S. T.et al. 1999. Recombinant vaccinia virus. In: Tindle, R. W. ed. Vaccines for Human Papillomavirus Infection and anogenital disease, 14th ed.. Medical Intelligence Unit Austin, Texas: R.G. Landes Company, pp. 69-90.

1997

• Nimako, M.et al. 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Research 57(21), pp. 4855-4861.
• Fiander, A. N.et al. 1997. Therapeutic vaccines for cervical cancer: concept and clinical results. Biodrugs -Auckland- 8(5), pp. 331-338. (10.2165/00063030-199708050-00001)

1996

• Borysiewicz, L. K.et al. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. The Lancet 347(9014), pp. 1523-1527. (10.1016/s0140-6736(96)90674-1)

1995

• Borysiewicz, L. K.et al. 1995. Development and initial clinical studies of TA-HPV in cervical cancer. European Journal of Cancer 31(supp 3), pp. 17-17. (10.1016/0959-8049(95)99882-z)